Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 2017, Article ID 6362804, 11 pages
https://doi.org/10.1155/2017/6362804
Research Article

Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario

1International Market Access Consulting, Montreal, QC, Canada
2University of Montréal, Faculty of Medicine, Montréal, QC, Canada
3Triton Pharma Inc., Concord, ON, Canada
4Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada
5Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada

Correspondence should be addressed to Louise Perrault; moc.sseccatekrami@tluarrep.esiuol

Received 18 October 2016; Accepted 31 January 2017; Published 20 February 2017

Academic Editor: José A. Oteo

Copyright © 2017 Louise Perrault et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. E. Falagas, E. K. Vouloumanou, A. G. Togias et al., “Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 9, pp. 1862–1877, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Colgan and M. Williams, “Diagnosis and treatment of acute uncomplicated cystitis,” American Family Physician, vol. 84, no. 7, pp. 771–776, 2011. View at Google Scholar · View at Scopus
  3. L. Nicolle, P. A. M. Anderson, J. Conly et al., “Uncomplicated urinary tract infection in women: current practice and the effect of antibiotic resistance on empiric treatment,” Canadian Family Physician, vol. 52, pp. 612–618, 2006. View at Google Scholar · View at Scopus
  4. T. M. Hooton, “Pathogenesis of urinary tract infections: an update,” Journal of Antimicrobial Chemotherapy, vol. 46, S1, pp. 1–7, 2000. View at Google Scholar · View at Scopus
  5. K. Gupta, T. M. Hooton, K. G. Naber et al., “International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases,” Clinical Infectious Diseases, vol. 52, no. 5, pp. e103–e120, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Kahlmeter, “An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS project,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 1, pp. 69–76, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Mazzulli, “Antimicrobial resistance trends in common urinary pathogens,” The Canadian Journal of Urology, vol. 8, pp. 2–5, 2001. View at Google Scholar · View at Scopus
  8. K. G. Naber, G. Schito, H. Botto, J. Palou, and T. Mazzei, “Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy,” European Urology, vol. 54, no. 5, pp. 1164–1178, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. S. L. Bermingham and J. F. Ashe, “Systematic review of the impact of urinary tract infections on health-related quality of life,” BJU International, vol. 110, no. 11, pp. E830–E836, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J. C. Nickel, J. C. Lee, J. E. Grantmyre, and D. Polygenis, “Natural history of urinary tract infection in a primary care environment in Canada,” The Canadian Journal of Urology, vol. 12, no. 4, pp. 2728–2737, 2005. View at Google Scholar · View at Scopus
  11. Institut National D'excellence En Santé Et En Services Sociaux (Inesss), “Guides cliniques en antibiothérapie—Série I: Infections urinaires chez l’adulte,” 2009, http://www.inesss.qc.ca/fileadmin/doc/CDM/UsageOptimal/Guides-serieI/CdM-Antibio1-InfectionsUrinaires-Adultes-fr.pdf.
  12. Paladin Labs Inc, Product Monograph: Monurol® (Fosfomycin Tromethamine) 3g Sachet, Paladin Labs Inc, St. Laurent, Canada, 2015.
  13. Anti-Infective Review Panel, Anti-Infective Guidelines for Community-Acquired Infections, 2013.
  14. E. Blondel-Hill and S. Fryters, Bugs & Drugs: an Antimicrobial/Infectious Diseases Reference, Alberta Health Services, Alberta, Canada, 2012.
  15. G. G. Zhanel, H. J. Adam, M. R. Baxter et al., “Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study,” The Journal of antimicrobial chemotherapy, vol. 68, pp. i7–i22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Karlowsky, P. R. S. Lagacé-Wiens, P. J. Simner et al., “Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 7, pp. 3169–3175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. W. J. McIsaac, T. Mazzulli, J. Permaul, R. Moineddin, and D. E. Low, “Community-acquired antibiotic resistance in urinary isolates from adult women in Canada,” Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 17, no. 6, pp. 337–340, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. Institut National D'Excellence En Santé Et En Services Sociaux (Inesss), Guides Cliniques en Antibiothérapie—Série II: Information Sheet on Bacterial Resistance, 2012, http://www.inesss.qc.ca/fileadmin/doc/INESSS/Outils/Guides_antibio_II/GUIDE_RESISTANCE_2012_web_EN.pdf.
  19. G. G. Zhanel, A. J. Walkty, and J. A. Karlowsky, “Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis,” Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 2016, Article ID 2082693, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Popovic, D. Steinort, S. Pillai, and C. Joukhadar, “Fosfomycin: an old, new friend?” European Journal of Clinical Microbiology and Infectious Diseases, vol. 29, no. 2, pp. 127–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Kahlmeter and H. O. Poulsen, “Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited,” International Journal of Antimicrobial Agents, vol. 39, no. 1, pp. 45–51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. G. C. Schito, K. G. Naber, H. Botto et al., “The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections,” International Journal of Antimicrobial Agents, vol. 34, no. 5, pp. 407–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. Ministry of Health and Long-Term Care, Ontario Drug Benefit Formulary/Comparative Drug Index, 2016, https://www.formulary.health.gov.on.ca/formulary/.
  24. Ministry of Health and Long-Term Care, Schedule of Benefits: Physician Services under the Health Insurance Act, 2016.
  25. Régie De L'assurance Maladie Du Québec (Ramq), “Manuel des médecins omnipraticiens,” Tech. Rep. 100, RAMQ, Quebec, Canada, 2015. View at Google Scholar
  26. Ordre Des Infirmières Et Infirmiers Auxiliaires Du Québec (OIIAQ), Les Services d'Urgence au Québec: Caractéristiques et Utilisation des Infirmières Auxiliaires, OIIAQ, Quebec, Canada, 2009.
  27. J. A. Mckinnell, N. S. Stollenwerk, C. W. Jung, and L. G. Miller, “Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis,” Mayo Clinic Proceedings, vol. 86, no. 6, pp. 480–488, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. H. C. Barry, M. H. Ebell, and J. Hickner, “Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies,” Journal of Family Practice, vol. 44, no. 1, pp. 49–60, 1997. View at Google Scholar · View at Scopus
  29. D. C. Henry Jr., R. B. Bettis, E. Riffer et al., “Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women,” Clinical Therapeutics, vol. 24, no. 12, pp. 2088–2104, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Iravani, I. Klimberg, C. Briefer, C. Munera, S. F. Kowalsky, and R. M. Echols, “A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection,” Journal of Antimicrobial Chemotherapy, vol. 43, supplement A, pp. 67–75, 1999. View at Google Scholar · View at Scopus
  31. J. M. McCarty, G. Richard, W. Huck et al., “A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women,” American Journal of Medicine, vol. 106, no. 3, pp. 292–299, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. D. A. Talan, W. E. Stamm, T. M. Hooton et al., “Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial,” JAMA, vol. 283, no. 12, pp. 1583–1590, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. C. A. M. McNulty, J. Richards, D. M. Livermore et al., “Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care,” Journal of Antimicrobial Chemotherapy, vol. 58, no. 5, pp. 1000–1008, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. R. Johnson and W. E. Stamm, “Diagnosis and treatment of acute urinary tract infections,” Infectious disease clinics of North America, vol. 1, no. 4, pp. 773–791, 1987. View at Google Scholar · View at Scopus
  35. M. Rosenberg, “Pharmacoeconomics of treating uncomplicated urinary tract infections,” International Journal of Antimicrobial Agents, vol. 11, no. 3-4, pp. 247–251, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. A. G. Carrie, C. J. Metge, D. M. Collins, G. K. M. Harding, and G. G. Zhanel, “Predictors of receipt of a fluoroquinolone versus trimethoprim-sulfamethoxazole for treatment of acute pyelonephritis in women in Manitoba, Canada,” Pharmacoepidemiology and Drug Safety, vol. 13, no. 12, pp. 863–870, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. G. G. Zhanel, J. A. Karlowsky, G. K. M. Harding et al., “A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 4, pp. 1089–1092, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Ceran, D. Mert, F. Y. Kocdogan et al., “A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,” Journal of Infection and Chemotherapy, vol. 16, no. 6, pp. 424–430, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Gupta, T. M. Hooton, and W. E. Stamm, “Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis,” Journal of Antimicrobial Chemotherapy, vol. 56, no. 1, pp. 243–246, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. M. A. Minassian, D. A. Lewis, D. Chattopadhyay, B. Bovill, G. J. Duckworth, and J. D. Williams, “A comparison between single-dose fosfomycin trometamol (Monuril®) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women,” International Journal of Antimicrobial Agents, vol. 10, no. 1, pp. 39–47, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. K. G. Naber and U. Thyroff-Friesinger, “Fosfomycin trometamol versus ofloxacin/Co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study,” Infection, vol. 18, supplement 2, pp. S70–S76, 1990. View at Publisher · View at Google Scholar · View at Scopus
  42. G. E. Stein, “Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection,” Clinical Therapeutics, vol. 21, no. 11, pp. 1864–1872, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Van Pienbroek, J. Hermans, A. A. Kaptein, and J. D. Mulder, “Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women,” Pharmacy World & Science, vol. 15, no. 6, pp. 257–262, 1993. View at Publisher · View at Google Scholar · View at Scopus
  44. Ministry of Health and Long-Term Care, Ontario Drug Benefit Formulary/Comparative Drug Index, Ontario Ministry of Health and Long-Term Care, Toronto, Canada, 42nd edition, 2015.
  45. OCCI Ontario Case Costing Initiative, OCCI Costing Analysis Tool 2016, https://hsimi.on.ca/hdbportal/.
  46. Canadian Antimicrobial Resistance Alliance (CARA), 2011, http://www.can-r.com/index.php.
  47. J. A. Karlowsky, A. J. Denisuik, P. R. S. Lagacé-Wiens et al., “In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 2, pp. 1252–1256, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. K. S. Ko, J. Y. Suh, K. R. Peck, M. Y. Lee, W. S. Oh, and K. T. Kwon, “In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood,” Diagnostic Microbiology and Infectious Disease, vol. 58, no. 1, pp. 111–115, 2007. View at Publisher · View at Google Scholar
  49. Triton Pharma, Product Monograph: Monurol® (Fosfomycin Tromethamine) 3g Sachet, Triton Pharma, Concord, Canada, 2012.
  50. G. Kahlmeter and P. Menday, “Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO·SENS project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections,” Journal of Antimicrobial Chemotherapy, vol. 52, no. 1, pp. 128–131, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Reynaert, D. Van Eyck, and J. Vandepitte, “Single dose fosfomycin trometamol versus multiple dose norfloxacin over three days for uncomplicated UTI in general practice,” Infection, vol. 18, no. 2, pp. S77–S79, 1990. View at Publisher · View at Google Scholar · View at Scopus
  52. J. W. Mouton, P. G. Ambrose, R. Canton et al., “Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective,” Drug Resistance Updates, vol. 14, no. 2, pp. 107–117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. American College of Obstetricians and Gynecologists, “ACOG Practice Bulletin No. 91: treatment of urinary tract infections in nonpregnant women,” Obstetrics & Gynecology, vol. 111, no. 3, pp. 785–794, 2008. View at Publisher · View at Google Scholar
  54. L. Almenar, B. Díaz, A. Quesada et al., “Cost-effectiveness analysis of cardiac resynchronization therapy in patients with NYHA i and nyha II heart failure in spain,” International Journal of Technology Assessment in Health Care, vol. 29, no. 2, pp. 140–146, 2013. View at Publisher · View at Google Scholar · View at Scopus